UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 26, 2019

PIERIS PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Nevada (State or other jurisdiction of incorporation) 255 State Street, 9th Floor Boston, MA

(Address of principal executive offices)

001-37471 (Commission File Number) 30-0784346 (IRS Employer Identification No.)

02109

(Zip Code)

Registrant's telephone number, including area code: 857-246-8998

N/A (Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.001 par value per share	PIRS	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company \blacksquare

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 8.01: Other Events.

On September 26, 2019, the European Respiratory Society published Pieris Pharmaceutical, Inc.'s (the "Company's") poster related to its phase 1 multiple ascending dose study of PRS-060, entitled *Multiple ascending dose study of an inhaled IL-4Ra antagonist, AZD1402/PRS-060, in mild asthmatics demonstrates robust FeNO reduction and a promising clinical profile for the treatment of asthma.* The poster is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

99.1 PRS-060 Multiple Ascending Dose Study Poster.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PIERIS PHARMACEUTICALS, INC.

Dated: September 26, 2019

/s/ Tom Bures


Tom Bures VP Finance

Multiple ascending dose study of the inhaled IL-4Ra antagonist, AZD1402/PRS-060, in mild asthmatics demonstrates robust FeNO reduction and a promising clinical profile for the treatment of asthma



PA3709

Bruns IB,¹ Fitzgerald MF,¹ Mensing G,¹ Stung M,¹ Pardali K,² Gardiner P,³ Keeling DJ,² Axelsson LT,² Olsson M,⁴ Ghobadi C,² Walsh O,⁵ McLendon K,⁹ Farinola N,⁷ Hatchuel L,⁶ Close DR² Pieris Pharmaceuticais, Boston, MA, USA: "Early Respiratory, Inflammation and Autoimmunity, Biopharmaceuticais R&D, AstraZeneca, Gothenburg, Sweden; "Clinical Pharmaceuticais R&D, AstraZeneca, Barting R&D, AstraZeneca, Gothenburg, Sweden; "Clinical Pharm



Poster presented at the ERS International Congress 2013, Machin, Spain, 28 September-2 October 2019